Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 11/20 | 0.43 |
| ▸ | CA2 | P00918 | 11/20 | 0.43 |
| ▸ | CA9 | Q16790 | 11/20 | 0.43 |
| ▸ | CA1 | P00915 | 10/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | MC3R | P41968 | 1/20 | 0.40 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL28321161 | 0.84 | ABCC9 (0.40) | CA12CA2CA9CA1CA14 | |
| SCHEMBL7835984 | 0.80 | SLC40A1 (0.41) | HSP90AA1ADORA3TSHRMC4RADRA1A | |
| SCHEMBL1536870 | 0.80 | CA12 (0.38) | CA12CA2CA9CA1CA14 | |
| SCHEMBL329658 | 0.78 | SLC40A1 (0.40) | HSP90AA1ADORA3TSHRMC4RADRA1A | |
| Hydrazine SCHEMBL27587071 | 0.77 | HSP90AA1 (0.39) | CA12CA2CA9CA1CA14 | |
| SCHEMBL2550700 | 0.76 | SLC40A1 (0.39) | CA12CA2CA9CA1CA14 | |
| SCHEMBL3155945 | 0.76 | SLC40A1 (0.39) | HSP90AA1ADORA3TSHRMC4RADRA1A | |
| SCHEMBL20019666 | 0.76 | SLC40A1 (0.39) | HSP90AA1ADORA3TSHRMC4RADRA1A | |
| SCHEMBL329659 | 0.76 | NAPRT (0.43) | HSP90AA1ADORA3TSHRMC4RADRA1A | |
| SCHEMBL10716052 | 0.74 | SLC40A1 (0.38) | HSP90AA1ADORA3TSHRMC4RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| EP-3953341-B1 | NOVEL OXADIAZOLE COMPOUNDS FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD (IN) | 2023-07-26 | — | — | EP | claimed |
| EP-3953341-A1 | NOVEL OXADIAZOLE COMPOUNDS FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI Industries Ltd. (IN) | 2022-02-16 | — | — | EP | claimed |
| CN-101217957-B | 2, 3-substituted pyrazine sulfonamides as CRTH2 inhibitors | MERCK SERONO SA | 2012-04-04 | — | — | CN | claimed |
| EP-1871374-B1 | 2,3 SUBSTITUTED PYRAZINE SULFONAMIDES AS INHIBITORS OF CRTH2 | MERCK SERONO SA (CH) | 2011-09-14 | — | — | EP | claimed |
| US-20090054447-A1 | 2,3 Substituted Pyrazine Sulfonamides as Inhibitors of CRTH2 | LABORATOIRES SERONO S.A. (CH) | 2009-02-26 | — | — | US | claimed |
| CN-101217957-A | 2,3 substituted pyrazine sulfonamides as inhibitors of CRTH2 | SERONO LAB (CH) | 2008-07-09 | — | — | CN | claimed |
| EP-1871374-A2 | 2,3 SUBSTITUTED PYRAZINE SULFONAMIDES AS INHIBITORS OF CRTH2 | Laboratoires Serono SA (CH) | 2008-01-02 | — | — | EP | claimed |
| WO-2006111560-A2 | 2,3 SUBSTITUTED PYRAZINE SULFONAMIDES AS INHIBITORS OF CRTH2 | LABORATOIRES SERONO S.A. (CH) | 2006-10-26 | — | — | WO | claimed |
| EP-0758327-A1 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1997-02-19 | — | — | EP | claimed |
| WO-1995030670-A2 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-16 | — | — | WO | claimed |
| CN-118515589-A | Synthesis method of sulfonamide compound | 台州学院 | 2024-08-20 | — | — | CN | disclosed |
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | disclosed |
| US-11999753-B2 | Tetrahydropyridopyrimidine pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4371979-A1 | FORMAMIDE DERIVATIVE AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT | Kumiai Chemical Industry Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| EP-0758327-A1 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995030670-A2 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
| US-4707551-A | PLANT GROWTH REGULATORS | CIBA-GEIGY CORPORATION (US) | 1987-11-17 | — | — | US | disclosed |
| US-3971740-A | DYES FOR POLYESTER FIBERS | CIBA-GEIGY AG (CH) | 1976-07-27 | — | — | US | disclosed |
| US-3903275-A | Medicated fish feeds and the treatment of fish diseases caused by bacteria | HOFFMANN LA ROCHE | 1975-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999753-B2 | Tetrahydropyridopyrimidine pan-KRas inhibitors | KRAS, NRAS, HRAS | CA12 4066/4885CA2 3675/4885CA9 2186/4885 |
| US-20090054447-A1 | 2,3 Substituted Pyrazine Sulfonamides as Inhibitors of CRTH2 | HRH2, HRH1, HRH4 | CA12 1200/4885CA2 668/4885CA9 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.